Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Business Wire•03/11/2026•08:30 ET
0
Key Highlights
- ➤Alnylam will present five-year HELIOS-B data, including two-year open-label extension results
- ➤HELIOS-B CPET analysis found vutrisiran preserved exercise capacity versus placebo over two years
- ➤HELIOS-B showed 28.2% lower all-cause mortality and recurrent CV events through 36 months
- ➤More than 1,000 real-world patients showed greater comorbidity burden among second-line vutrisiran initiators
- ➤ISA analysis found statistically significant quality-of-life benefits on neuropathy measures versus placebo
Expert Statements
Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
“Alnylam continues to pioneer TTR silencing through RNAi innovation, with an expanding evidence base that reinforces the potential of AMVUTTRA to transform ATTR care”
Yvonne Greenstreet, Chief Executive Officer of Alnylam Pharmaceuticals
“The landmark HELIOS-B study established a strong foundation for AMVUTTRA, and the research being presented at AHA and ISA reflects our determination to build on this progress and drive the next chapter in the treatment of this progressive disease.”
Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA(®) (vutrisiran) at AHA and ISA 2026
– Late-Breaking Presentation at AHA Will Feature Long-Term Results from the HELIOS-B Phase 3 Study, Including Two Years of Open-Label Extension Data in Patients with ATTR-CM –
Get started
Create a free account to read the full story.